Idiopathic Pulmonary Fibrosis Market - Forecast(2021 - 2026)

Report Code: HCR 72933 Report Format: PDF + Excel (Delivery in 48 Hrs)

Idiopathic Pulmonary Fibrosis Market Overview

Idiopathic Pulmonary Fibrosis Market size is forecast to reach $3.27 billion by 2025, growing at a CAGR of 12.39% during the forecast period 2020-2025. Idiopathic pulmonary fibrosis is a disease in which lung tissues become thick and stiff over time which results in reducing the oxygen carrying capacity of the tissues. Increasing prevalence of idiopathic pulmonary fibrosis and increasing geriatric population are the major factors driving the growth of the market. Increase in a number of patients suffering from idiopathic pulmonary fibrosis activities owing to smoking is set to further enhance the overall market demand of idiopathic pulmonary fibrosis during the forecast period 2020-2025. 

Report Coverage

The report: “Idiopathic Pulmonary Fibrosis Market Forecast (2020-2025)”, by IndustryARC, covers an in depth analysis of the following segments of the Idiopathic Pulmonary Fibrosis Market. 

By Product Type: Pirfenidone and Nintedanib
By Type: Antifibrotic Agents, Immunosuppressant Drugs and Tyrosine Kinase Inhibitors.
By Application: Malaria, Arrhythmias, Others
By End Users: Hospitals, Long term Care Facilities, Academics and Research Organization, Ambulatory Surgical Centers, Others.
By Geography: North America, Europe, Asia Pacific and Rest of the World (RoW).

Key Takeaways

  • North America dominates the Idiopathic Pulmonary Fibrosis Market in 2019 owing to the increasing number of idiopathic pulmonary fibrosis incidence and availability of drugs. The Idiopathic Pulmonary Fibrosis Market scope for different regions will be provided in the final report.
  • Increasing prices of the drugs and Increase in the number of people smoking cigarettes is likely to aid in the market growth of idiopathic pulmonary fibrosis.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Idiopathic Pulmonary Fibrosis Market report.
  • Unavailability of the treatment options that can completely cure the disease and increase in incidence of fibrotic disease is poised to create hurdles for the Idiopathic Pulmonary Fibrosis Market.

Product- Segment Analysis

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease of unknown etiology characterized by dyspnea and deterioration of lung function, with poor quality of life and a median survival time. Pirfenidone inhibits fibroblast proliferation and collagen synthesis and deposition, both in vitro and in animal models. Nintedanib is a tyrosine kinase inhibitor with antifibrotic properties that has also been shown to significantly reduce the progression of the disease. Nintedanib is effective and well tolerated for the treatment of IPF in mild, moderate and severe stages of the disease. It is estimated that pirfenidone will be the highest growing segment of the idiopathic pulmonary fibrosis market during the forecast period 2020-2025.

Application - Segment Analysis

People who have idiopathic pulmonary fibrosis, atrial arrhythmias, such as atrial flutter and atrial fibrillation, are the most common type of abnormal rhythm. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease and thus it is estimated that Arrhythmias will be the highest growing segment in the forecast period.

Geography - Segment Analysis

North America dominated the idiopathic pulmonary fibrosis market in 2019 with a share of more than 39.7%, followed by Europe owing to the increasing prevalence of idiopathic pulmonary fibrosis and the increasing geriatric population. Increasing number of patients suffering from fibrotic disease is increasing the growth of the idiopathic pulmonary fibrosis market in this region.
However, Europe   is estimated to grow at a higher CAGR during the forecast period 2020-2025 .This is attributed to the rising number of cigarette smoking people, rising lifestyles, increasing provenance of the cardiovascular diseases and increasing awareness about health is increasing the growth of the idiopathic pulmonary fibrosis market in this region.

Drivers – Idiopathic Pulmonary Fibrosis Market 


  • Rise in Geriatric Population

Rise in Geriatric Population is increasing the growth of the idiopathic pulmonary fibrosis market owing to the increase in the number of aging population. Increase in elderly individuals is estimated to result in rise in incidence of lung disorders, which in turn increases the risk for idiopathic pulmonary fibrosis, thereby fueling the market growth. Idiopathic pulmonary fibrosis may also be caused due to genetic predisposition or develop from other lung condition. Some of the medical conditions, which may develop in a patient with idiopathic pulmonary fibrosis include obstructive sleep apnea, chronic obstructive pulmonary disease, coronary artery disease and gastro oesophagal reflux disease. 

  • The increasing number of idiopathic pulmonary fibrosis incidence

The increasing number of idiopathic pulmonary fibrosis incidence is increasing the growth of the idiopathic pulmonary fibrosis market. Idiopathic pulmonary fibrosis is a type of lung disease that results in scarring of the lungs for an unknown reason. The clinical symptoms of idiopathic pulmonary fibrosis are nonspecific and can be shared with many pulmonary and cardiac diseases. The fibrosis in idiopathic pulmonary fibrosis has been linked to cigarette smoking, environmental factors (e.g. occupational exposure to gases, smoke, chemicals or dusts), other medical conditions including gastroesophageal reflux disease (GERD) or to genetic predisposition. Thus, increasing the growth of the idiopathic pulmonary fibrosis incidence market.

Challenges – Idiopathic Pulmonary Fibrosis Market

 

  • Unavailability of the treatment options

Some of the factors which can impede the growth of the idiopathic pulmonary fibrosis market are unavailability of the treatment options that can completely cure the disease and increase in incidence of fibrotic disease.  

Idiopathic Pulmonary Fibrosis   Industry Outlook

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the idiopathic pulmonary fibrosis market. In 2019, Idiopathic Pulmonary Fibrosis Market share is consolidated by the top ten players present in the market. Idiopathic Pulmonary Fibrosis  , top 10 companies are  Biogen, Inc , Boehringer Ingelheim Gmbh ,  Bristol-Myers Squibb Company , Cipla Inc , F. Hoffmann-La Roche Ag , Fibrogen, Inc , Galapagos Nv , Medicinova, Inc , Merck Co , Inc  and Prometic Life Science Inc among others.

Acquisitions/Product Launches

  • In March 2019, Biogen Inc., announced agreement to acquire Nightstar Therapeutics.
  • In November 2018, Cipla Inc., announced agreement with Avenue Therapeutics.

For more Lifesciences and Healthcare related reports, please click here
1. Idiopathic Pulmonary Fibrosis Market - Overview
    1.1 Definitions and Scope
2. Idiopathic Pulmonary Fibrosis Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Type of Drug
    2.3 Key trends by Type
    2.4 Key trends by Application
    2.5 Key trends by Geography
3. Idiopathic Pulmonary Fibrosis Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Idiopathic Pulmonary Fibrosis Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Idiopathic Pulmonary Fibrosis Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Idiopathic Pulmonary Fibrosis Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Idiopathic Pulmonary Fibrosis Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Idiopathic Pulmonary Fibrosis Market – By Product Type (Market Size –$Million/$Billion)
    8.1 Pirfenidone
    8.2 Nintedanib
9. Idiopathic Pulmonary Fibrosis Market – By Type (Market Size –$Million/$Billion)
    9.1 Antifibrotic Agents
    9.2 Immunosuppressant Drugs
    9.3 Tyrosine Kinase Inhibitors.
10. Idiopathic Pulmonary Fibrosis Market  – By Application(Market Size –$Million/$Billion)
    10.1 Malaria
    10.2 Arrhythmias
    10.3 Others
11. Idiopathic Pulmonary Fibrosis Market  – By End User(Market Size –$Million/$Billion)
    11.1 Hospitals
    11.2 Long Term Care Facilities
    11.3 Academic and Research Organizations
    11.4 Ambulatory Surgical Centers
    11.5 Others
12. Idiopathic Pulmonary Fibrosis Market - By Geography 
    12.1 North America
        12.1.1 U.S.
        12.1.2 Mexico
        12.1.3 Canada
    12.2 Europe
        12.2.1 U.K.
        12.2.2 France
        12.2.3 Germany
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Rest of Europe
    12.3 Asia Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia
        12.3.6 New Zealand
        12.3.7 Rest of APAC
    12.4 Rest of the World
        12.4.1 Middle East
        12.4.2 Africa
        12.4.3 South America
13. Idiopathic Pulmonary Fibrosis Market - Entropy
14. Idiopathic Pulmonary Fibrosis Market – Industry/Segment Competition Landscape (Premium) 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
        14.1.4 Best Practices for Companies
15. Idiopathic Pulmonary Fibrosis Market – Key Company List by Country Premium (Premium)
16. Idiopathic Pulmonary Fibrosis Market Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Idiopathic Pulmonary Fibrosis Market, By Type Of Drug Market 2019-2024 ($M)
1.1 Pirfenidone Market 2019-2024 ($M) - Global Industry Research
1.2 Nintedanib Market 2019-2024 ($M) - Global Industry Research
2.Global Idiopathic Pulmonary Fibrosis Market, By Type Of Drug Market 2019-2024 (Volume/Units)
2.1 Pirfenidone Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 Nintedanib Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Idiopathic Pulmonary Fibrosis Market, By Type Of Drug Market 2019-2024 ($M)
3.1 Pirfenidone Market 2019-2024 ($M) - Regional Industry Research
3.2 Nintedanib Market 2019-2024 ($M) - Regional Industry Research
4.South America Idiopathic Pulmonary Fibrosis Market, By Type Of Drug Market 2019-2024 ($M)
4.1 Pirfenidone Market 2019-2024 ($M) - Regional Industry Research
4.2 Nintedanib Market 2019-2024 ($M) - Regional Industry Research
5.Europe Idiopathic Pulmonary Fibrosis Market, By Type Of Drug Market 2019-2024 ($M)
5.1 Pirfenidone Market 2019-2024 ($M) - Regional Industry Research
5.2 Nintedanib Market 2019-2024 ($M) - Regional Industry Research
6.APAC Idiopathic Pulmonary Fibrosis Market, By Type Of Drug Market 2019-2024 ($M)
6.1 Pirfenidone Market 2019-2024 ($M) - Regional Industry Research
6.2 Nintedanib Market 2019-2024 ($M) - Regional Industry Research
7.MENA Idiopathic Pulmonary Fibrosis Market, By Type Of Drug Market 2019-2024 ($M)
7.1 Pirfenidone Market 2019-2024 ($M) - Regional Industry Research
7.2 Nintedanib Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
2.Canada Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
3.Mexico Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
4.Brazil Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
5.Argentina Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
6.Peru Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
7.Colombia Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
8.Chile Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
9.Rest of South America Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
10.UK Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
11.Germany Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
12.France Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
13.Italy Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
14.Spain Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
15.Rest of Europe Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
16.China Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
17.India Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
18.Japan Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
19.South Korea Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
20.South Africa Idiopathic Pulmonary Fibrosis Market Revenue, 2019-2024 ($M)
21.North America Idiopathic Pulmonary Fibrosis By Application
22.South America Idiopathic Pulmonary Fibrosis By Application
23.Europe Idiopathic Pulmonary Fibrosis By Application
24.APAC Idiopathic Pulmonary Fibrosis By Application
25.MENA Idiopathic Pulmonary Fibrosis By Application
26.Biogen, Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Boehringer Ingelheim Gmbh, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Bristol-Myers Squibb Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Cipla Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.F. Hoffmann-La Roche Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Fibrogen, Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Galapagos Nv, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Medicinova, Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Prometic Life Science Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)